Damianaki Aikaterini, Stambolliu Emelina, Alexakou Zoi, Petras Dimitrios
Department of Nephrology, Ippokrateion University Hospital, Athens, Greece.
Service of Nephrology and Hypertension, Lausanne University Hospital, Lausanne, Switzerland.
Kidney Res Clin Pract. 2023 May;42(3):298-311. doi: 10.23876/j.krcp.22.223. Epub 2023 Mar 29.
Hemoperfusion has been considered a promising adjuvant treatment for chronic diseases and some acute states when specific removal of pathogenic factors from the bloodstream is desired. Over the years, advances in adsorption materials (e.g., new synthetic polymers, biomimetic coating, and matrixes with novel structures) have renewed scientific interest and expanded the potential therapeutic indications of hemoperfusion. There is growing evidence to suggest a prominent place for hemoperfusion as an adjuvant treatment in the setting of sepsis or severe coronavirus disease 2019 and as a therapeutic option for chronic complications associated with accumulated uremic toxins in patients with end-stage renal disease. This literature review will describe the principles, therapeutic perspectives, and the emerging role of hemoperfusion as a complementary therapy for patients with kidney disease.
当需要从血液中特异性去除致病因素时，血液灌流一直被认为是治疗慢性疾病和某些急性病症的一种有前景的辅助治疗方法。多年来，吸附材料（如新型合成聚合物、仿生涂层和具有新颖结构的基质）的进展重新激发了科学兴趣，并扩大了血液灌流的潜在治疗适应症。越来越多的证据表明，血液灌流作为脓毒症或重症2019冠状病毒病的辅助治疗方法，以及作为终末期肾病患者与尿毒症毒素蓄积相关慢性并发症的治疗选择，具有重要地位。这篇文献综述将描述血液灌流的原理、治疗前景以及作为肾病患者补充治疗方法的新作用。
